Business
Avacta & Pall Corp form new collaborative venture
Avacta & Pall Corp form new collaborative venture.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 2762I Avacta Group PLC 13 June 2011 \n \n\n \n \n\n\n\n\nPress release\n\n\n13 June 2011\n\n\n\n\n \nAvacta Group plc\n(\"Avacta\" or \"the Group\")\n \nAvacta and Pall Life Sciences form new analytical services collaboration \nPartnership creates a market leading bioprocess analysis service\n \nAvacta Group plc (AIM:AVCT), a leading provider of analytics and diagnostics to the pharmaceutical and animal healthcare sectors, is pleased to announce that it has entered into a collaborative venture with Pall Corporation (NYSE:PLL) (\"Pall\"), a global leader in filtration, separation and purification, to deliver a market leading analytical service to biopharmaceutical developers.\n \nUnder the terms of the collaboration Pall will utilise the services of Avacta and market joint services with a focus in North America, and in certain other regions globally where Avacta is not currently represented. Pall's expertise in developing high yield purification processes for biopharmaceutical compounds is well recognised but the current state-of-the-art in process optimisation is enhanced by more information on how the structure and stability of compounds are affected by manufacturing or purification processes. Avacta's analytical capabilities provide a significant value add in this, and other areas, ensuring Pall's analytical service offering is the most comprehensive option for its customers involved in drug development.\n \nThe combined services are aimed at reducing drug development risk by giving customers greater insight into the effects of their manufacturing processes. They will leverage Avacta's expertise in analysis at the very early stages in drug development to provide customers with new opportunities to screen molecules early on, for their manufacturability as well as their functional properties.\n \nThe US biopharmaceuticals market is worth around $100bn and the provision of contract services into this rapidly growing sector is worth several billion dollars annually. Together the two companies will provide a market leading analytical service to assist biological drug developers reduce the costs of drug development through improved compound screening and optimisation of manufacturing and purification conditions. The services will be delivered through Pall's Scientific L...